Abstract
Direct virus inoculations and viral oncolysates may induce temporary remissions and prolong life with reduced tumor burden, or decrease relapse rates but fall short of curing human cancers. We propose: (i) investigations of Cassel's 73-T, an Ehrlich's mouse ascites carcinoma-adapted Newcastle disease virus (NDV) strain that so effectively reduced relapse rates in malignant melanoma if it is an admixture or a recombinant with a murine parvovirus; (ii) transfection of prostatic carcinoma cells with the TRMP gene; (iii) transfection of sarcoma cells with the fas gene followed by treatment with anti-fas monoclonal antibodies, and (iv) treatment of metastatic tumors with a parvovirus incorporating the apoptosis-inducer Ad5 E1A gene. Thus, replicating virions and haphazard generation of cytokines in the inoculated host could be replaced with transfection of single genes of well-defined, limited but selected efficacy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
